Hande Turna

8.7k citations
63 papers · 7.2k · 2 hit papers · h-index 14

Impact in

  • Oncology top 0.5%
    • Cancer Immunotherapy and Biomarkers
    • Lung Cancer Research Studies
    • Inflammatory Biomarkers in Disease Prognosis
    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment
    • Brain Metastases and Treatment

Papers in

    • Cancer Immunotherapy and Biomarkers 8
    • Colorectal Cancer Surgical Treatments 5
    • Pancreatic and Hepatic Oncology Research 2
    • Breast Cancer Treatment Studies 8

Hande Turna

57 papers receiving 7.1k citations

Hande Turna's Hit Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial 2019 · 2.7k citations
2.7k0+3+6Years since publication1k2k3k

Peers

Hande Turna
Comparison fields: 5 of 83
  • Oncology 4.9k
  • Pulmonary and Respiratory Medicine 2.2k
  • Cancer Research 208
  • Radiology, Nuclear Medicine and Imaging 201
  • Statistics and Probability 111
Replace Lucas Vieira dos Santos with:
Lucas Vieira dos Santos Brazil
Anna V. Alyasova Russia
Graham Lawrence Cohen United States
Jaromı́r Roubec Czechia
Melanie A. Leiby United States
Gregory Landers United States
Mary J. Fidler United States
Iveta Kudaba United States
Leona Koubková Czechia
Waldemar Szpak Germany
Hande Turna relative to Lucas Vieira dos Santos Brazil Lucas Vieira dos Santos's profile →
Citations per field
00.5×1.5×2×2.4×
Lucas Vieira dos Santos · 1×
Citations per year

Countries citing papers authored by Hande Turna

Since Specialization
Citations

This map shows the geographic impact of Hande Turna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hande Turna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hande Turna more than expected).

Fields of papers citing papers by Hande Turna

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hande Turna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hande Turna. The network helps show where Hande Turna may publish in the future.

Co-authors

The 25 scholars most cited alongside Hande Turna, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hande Turna Line = papers co-authored together Hande Turna links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 63 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Hit paper breakdown →
20163966
2
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Hit paper breakdown →
20192712
3 201258
4 200438
5 200736
6 202030
7 201327
8 199921
9 200620
10 200717
11
Clinicopathologic and prognostic evaluation of invasive breast carcinoma molecular subtypes and GATA3 expression.
201117
12 201217
13 200716
14 200914
15 202314
16
Relation of serum vascular endothelial growth factor as an angiogenesis biomarker with nitric oxide & urokinase-type plasminogen activator in breast cancer patients.
200712
17 200711
18 201311
19 201911
20
Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer.
201310

About Hande Turna

Hande Turna is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Reproductive Medicine and Pathology and Forensic Medicine, having authored 63 papers that have together received 7.2k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (8 papers), Breast Cancer Treatment Studies (8 papers), Lung Cancer Treatments and Mutations (6 papers), Colorectal Cancer Surgical Treatments (5 papers), Ovarian cancer diagnosis and treatment (5 papers), Sarcoma Diagnosis and Treatment (3 papers), Lymphoma Diagnosis and Treatment (3 papers) and Pancreatic and Hepatic Oncology Research (2 papers). The work is most often cited by research in Oncology (4.9k citations), Pulmonary and Respiratory Medicine (2.2k citations), Cancer Research (208 citations), Radiology, Nuclear Medicine and Imaging (201 citations) and Statistics and Probability (111 citations). Hande Turna has collaborated with scholars based in Türkiye, Israel and Sweden. Frequent co-authors include Mustafa Özgüroğlu, Ahmet Erkan Bilici, Süheyla Serdengeçti, Nil Molinas Mandel, Şennur İlvan, Deniz Güncel Tural, Fatih Selçukbırıcık, İbrahim Adaletli, Sergülen Dervişoğlu and Mehmet Akif Öztürk. Their work appears in journals such as Medical Oncology, International Journal of Gynecological Cancer, The Lancet, Lung Cancer and BMC Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact